BackGenetic Technologies Overview

Genetic Technologies Total Liabilities

Track Genetic Technologies's total liabilities ($4.4M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$4.36M
17.93% YoYΔ $662445.00 vs prior year quarter

Peer average

Loading

Genetic Technologies Total Liabilities History

Loading

Genetic Technologies vs. peers: Total Liabilities Comparison

Loading

Genetic Technologies Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Genetic Technologies (GENE) FAQ

Genetic Technologies (GENE) currently reports a total liabilities of $4.4M as of June 2024. That compares with $3.7M in the prior-year period — up 17.9% year over year. Use the charts on this page to explore Genetic Technologies's total liabilities history and peer comparisons.

Genetic Technologies's total liabilities increased from $3.7M to $4.4M — a 17.9% year-over-year increase (period ending June 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Genetic Technologies reported $4.4M in total liabilities as of June 2024. That compares with $3.7M in the prior-year period — up 17.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $4.4M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Genetic Technologies, and consider following GENE for alerts when major investors trade the stock.

Genetic Technologies is classified in the Healthcare sector. On total liabilities, it currently shows $4.4M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing GENE with unrelated industries.